Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma.

导出 LinkOut

翻译打印收藏纠错

作者： Run-Jie,Wang ^[1] ; Rui-Quan,Ke ^[1] ; Yi-Feng,Yu ^[1] ; Guan-Zhong,Lu ^[1] ; San-Gang,Wu ^[1]

作者单位： Department of Radiation Oncology, Xiamen Cancer Quality Control Center, Xiamen Cancer Center, Xiamen Key Laboratory of Radiation Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. ^[1]

关键词 anti-EGFR nasopharyngeal carcinoma nimotuzumab outcome radiotherapy

DOI 10.3389/fphar.2024.1366853

PMID 38576484

发布时间 2024-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2024年15卷

1366853页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Addition of nimotuzumab to concurrent chemoradiotherapy after induction chemotherapy improves outcomes of patients with locally advanced nasopharyngeal carcinoma.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除